Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.

@article{Judson2001RandomisedPI,
  title={Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.},
  author={Ian Judson and John Radford and Michael Harris and Jean-Yves Blay and Quirinis G C M Van Hoesel and Axel le Cesne and Allan T. van Oosterom and Mark Clemons and Claus Kamby and Catherine Hermans and J J Whittaker and Eugenio Donato di Paola and Jaap Verweij and Susanne Kaasgaard Nielsen},
  journal={European journal of cancer},
  year={2001},
  volume={37 7},
  pages={870-7}
}
CAELYX/DOXIL, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types. In this prospective randomised trial, 94 eligible patients with advanced soft-tissue sarcoma (STS) were treated, 50 with CAELYX (50 mg/m(2) by a 1 h intravenous (i.v.) infusion every 4 weeks) and 44 with doxorubicin (75 mg/m(2) by an i.v. bolus every 3 weeks). Histological subtypes were evenly matched, 33% were leiomyosarcoma (CAELYX: 18… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 100 extracted citations

Similar Papers

Loading similar papers…